Magnesium deficiency promotes a pro-atherogenic phenotype in cultured human endothelial cells via activation of NFkB

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 11, 2010, Pages 952-958

  Ferrè, Silvia ^a   Baldoli, Erika ^a   Leidi, Marzia ^a   Maier, Jeanette A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytokine; Endothelial cell; Magnesium; MMP; NFkB

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROLOX C;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MAGNESIUM DEFICIENCY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; ZYMOGRAPHY;

ATHEROSCLEROSIS; BLOTTING, WESTERN; CELLS, CULTURED; CHEMOKINE CCL5; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MAGNESIUM; MAGNESIUM DEFICIENCY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PLATELET-DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956652811     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.06.016     Document Type: Article

References (33)

1. Galley H.F., Webster N.R. Physiology of the endothelium. Br. J. Anaest. 2004, 93:105-113.
2. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J. 2009, 73:595-601.
3. Esper R.J., Nordaby R.A., Vilariño J.O., Paragano A., Cacharrón J.L., Machado R.A. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol. 2006, 5:4.
4. Maier J.A. Low magnesium and atherosclerosis: an evidence-based link. Mol. Aspects Med. 2003, 24:137-146.
5. Ravn H.B., Korsholm T.L., Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21:858-862.
6. Shechter M., Sharir M., Labrador M.J., Forrester J., Silver B., Bairey Merz C.N. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000, 102:2353-2358.
7. Liao F., Folsom A.R., Brancati F.L. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 1998, 136:480-490.
8. Ford E.S., Mokdad A.H. Dietary magnesium intake in a national sample of US adults. J. Nutr. 2003, 133:2879-2882.
9. Maier J.A., Malpuech-Brugère C., Zimowska W., Rayssiguier Y., Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim. Biophys Acta-Mol. Bas. Dis. 2004, 1689:13-21.
10. Killilea D., Maier J.A. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnes. Res. 2008, 21:77-82.
11. Paravicini T.M., Yogi A., Mazur A., Touyz R.M. Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited hypomagnesemia. Hypertension 2009, 53:423-429.
12. Mazur Test A. Magnesium and the inflammatory response: potential physiopathological implications. Arch. Biochem. Biophys. 2007, 458:48-56.
13. Kempe S., Kestler H., Lasar A., Wirth T. NFkB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucl. Ac. Res. 2005, 33:5308-5319.
14. Denk A., Goebeler M., Schmid S., Berberich I., Ritz O., Lindemann D., Ludwig S., Wirth T. Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J. Biol. Chem. 2001, 276:28451-28458.
15. Wolf F.I., Trapani V., Simonacci M., Ferré S., Maier J.A. Magnesium deficiency and endothelial dysfunction: is oxidative stress involved?. Magnes. Res. 2008, 21:58-64.
16. Mabile L., Fitoussi G., Periquet B., Schmitt A., Salvayre R., Nègre-Salvayre A. Alpha-tocopherol and trolox block the early intracellular events (TBARS and calcium rises) elicited by oxidized low density lipoproteins in cultured endothelial cells. Free Radic. Biol. Med. 1995, 19:177-187.
17. Baker A.H., Edwards D.R., Murphy G. Metalloprotease inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 2002, 115:3719-3727.
18. Wolf F.I., Cittadini A.R., Maier J.A. Magnesium and tumors: ally or foes?. Cancer Treat. Rev. 2009, 35:378-382.
19. Verive M.J., Irazuzta J., Steinhart C.M., Orlowski J.P., Jaimovich D.G. Evaluating the frequency rate of hypomagnesemia in critically ill pediatric patients by using multiple regression analysis and a computer-based neural network. Crit. Care Med. 2000, 28:3534-3539.
20. Glaudemans B., van der Wijst J., Scola R.H., Lorenzoni P.J., Heister A., van der Kemp A.W., Knoers N.V., Hoenderop J.G., Bindels R.J. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J. Clin. Invest. 2009, 119:936-942.
21. Laires M.J., Monteiro C.P., Bicho M. Role of cellular magnesium in health and human disease. Front. Biosci. 2004, 9:262-276.
22. Monaco C., Andreakos E., Kiriakidis S., Mauri C., Bicknell C., Foxwell B., Cheshire N., Paleolog E., Feldmann M. Canonical pathway of NFkB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5634-5639.
23. Altura B.M., Kostellow A.B., Zhang A., Li W., Morrill G.A., Gupta R.K., Altura B.T. Expression of NFkB and proto-oncogenes c-fos and c-jun are induced by low magnesium in aortic and cerebral vascular smooth muscle cells: possible link to hypertension, atherogenesis and stroke. Am. J. Hypertens. 2003, 16:701-707.
24. Rochelson B., Dowling O., Schartz N., Metz C.N. Magnesium sulphate suppresses inflammatory responses by human umbilical endothelial cells through the NFkB pathway. J. Reprod. Immunol. 2007, 73:101-107.
25. Asai T., Nakatani T., Tamada S., Kuwabara N., Yamanaka S., Tashiro K., Nakao T., Komiya T., Okamura M., Kim S., Iwao H., Miura K. Activation of transcription factors AP-1 and NFkB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation. Transplantation 2003, 7:1040-1044.
26. Khachigian L.M., Resnick N., Gimbrone M.A., Collins T. Nuclear factor-kappa B interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clin. Invest. 1995, 96:169-175.
27. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
28. Ross R., Masuda J., Raines E.W., Gown A.M., Katsuda S., Sasahara M., Malden L.T., Masuko H., Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990, 248:1009-1012.
29. Barrett T.B., Benditt E.P. Sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery. Proc. Natl Acad. Sci. U.S.A. 1987, 84:1099-1103.
30. Zernecke A., Shagdarsuren E., Weber C. Chemokines in atherosclerosis. An update. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1897-1908.
31. Zhu S.N., Chen M., Jongstra-Bilen J., Cybulsky M.I. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J. Exp. Med. 2009, 206:2141-2149.
32. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
33. Volcik K.A., Campbell S., Chambless L.E., Coresh J., Folsom A.R., Mosley T.H., Ni H., Wagenknecht L.E., Wasserman B.A., Boerwinkle E. MMP-2 genetic variation is associated with measures of fibrous cap thickness: the Atherosclerosis Risk in Communities Carotid MRI Study. Atherosclerosis 2010, 210:188-193.